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Abstract:	 Radiotherapy	 has	 been	 advocated	 as	 an	 alternative	 treatment	 in	 early	 Dupuytren’s	21	
Disease.	We	have	systematically	 reviewed	the	evidence	on	the	use	of	 radiotherapy	 in	Dupuytren’s	22	
disease.	 Only	 six	 articles	 met	 a	 minimum	 set	 standard,	 five	 of	 which	 were	 retrospective	 cohort	23	
studies	 and	 one	 a	 randomised	 controlled	 study.	 A	 total	 of	 770	Dupuytren's	 hands,	 nearly	 all	with	24	
Tubiana	stage	0-1	disease,	were	irradiated	with	an	average	30	Gy.	Disease	regression	ranged	from	0-25	
56%,	stability	from	14-98%	and	progression	from	2-86%.	Salvage	surgery	was	successful	in	all	cases	26	
of	 disease	 progression	 post-radiotherapy.	 There	 were	 no	 reports	 of	 adverse	 wound	 healing	27	
problems	 associated	 with	 such	 surgery	 or	 radiotherapy-associated	 malignancy.	 On	 balance,	28	
radiotherapy	 should	be	 considered	an	unproven	 treatment	 for	early	Dupuytren's	disease	due	 to	a	29	
scarce	evidence	base	and	unknown	long-term	adverse	effects.	Well-designed	randomised	controlled	30	
studies	are	required	to	confirm	the	benefits	of	radiotherapy	treatment.		31	
Level	of	evidence:	II	32	
Introduction	33	
Radiotherapy	is	sometimes	used	as	an	adjunct	in	the	treatment	of	benign	conditions,	such	as	keloid	34	
scars,	which	are	characterized	by	 increased	proliferative	cellular	activity.	 In	Dupuytren’s	disease,	 it	35	
has	been	proposed	that	low	dose	irradiation	may	inhibit	fibroblast	proliferation	and	induce	an	anti-36	
inflammatory	effect	mediated	by	 inhibition	of	the	 innate	 immune	response	and	activation	of	nitric	37	
oxide	synthetase	(NOS)	pathways	(Arenas	et	al.,	2012;	Seegenschmiedt	et	al.,	2001).	A	dosage	of	30-38	
32	Gy	is	widely	used	in	the	treatment	of	benign	diseases	and	similar	doses	have	been	used	to	treat	39	
Dupuytren’s	 disease	 (Royal	 College	 of	 Radiologists.,	 2015).	 The	 only	 prospective	 study	 of	40	
radiotherapy	 in	 Dupuytren’s	 disease	 advocates	 its	 use	 in	 early	 stage	 disease	 only,	 as	 “the	41	
radiobiological	 potential	 of	 ionizing	 radiation	 is	 limited	 to	 early	 stages,	 as	 long	 as	 proliferating	42	
fibroblasts	exist	as	the	predominant	radiosensitive	target”	(Seegenschmiedt	et	al.,	2001).	43	
3	
	
Radiation	fibrosis	is	a	well-characterized	late	effect	of	radiotherapy	(Barker	et	al.,	2015)	and	the	use	44	
of	a	fibrosis-inducing	modality	of	therapy	to	treat	a	fibrosing	condition	may,	perhaps,	seem	counter-45	
intuitive.	 Hence,	 the	 use	 of	 radiotherapy	 in	 Dupuytren’s	 disease	 remains	 both	 limited	 and	46	
controversial	 amongst	 hand	 surgeons.	 Specifically,	 the	 efficacy	 of	 radiotherapy	 in	 managing	47	
Dupuytren’s	disease	 remains	uncertain,	 the	 longer-term	risks	unclear	and	whether	 irradiation	may	48	
complicate	subsequent	surgery	 remains	a	concern.	 In	 the	UK,	current	National	 Institute	 for	Health	49	
and	Care	Excellence	 (NICE)	 guidance	permits	 the	use	of	 radiotherapy	 in	early	Dupuytren’s	disease	50	
and	there	are	a	small	number	of	NHS	and	private	clinics	that	offer	this	service.		51	
The	aim	of	this	study	was	to	review	the	available	evidence	for	the	treatment	of	Dupuytren’s	disease	52	
with	radiotherapy.		53	
	54	
Methods	55	
An	advanced	search	was	performed	on	PubMed,	Google	Scholar	and	the	Cochrane	Library.	Specific	56	
vocabulary	 terms,	 key	words	and	 synonyms	were	entered	as	part	of	 a	 systematic	 search	 strategy.	57	
The	terms	and	keywords	were	also	joined	together	in	differing	combinations.	The	search	terms	used	58	
included:	Dupuytren’s	disease,	Dupuytren’s	contracture,	Dupuytren	Disease,	Dupuytren	Contracture,	59	
morbus	 Dupuytren,	 radiotherapy,	 radiation,	 therapy	 and	 non-surgical.	 The	 majority	 of	 articles	60	
published	on	the	use	of	radiotherapy	were	in	German.	As	a	result,	German	articles	were	translated	61	
and	 included.	 No	 specific	 date	 range	was	 used	 and	 articles	were	 found	 dating	 back	 to	 1985.	 The	62	
reference	 lists	 for	 all	 included	 papers	 were	 screened	 for	 any	 outstanding	 articles.	 	 Papers	 using	63	
repeated	 data	 sets	 were	 removed	 to	 avoid	 duplication.	 This	 was	 achieved	 by	 comparing	 author	64	
names	and	number	of	patients.	All	 included	articles	were	evaluated	 in	 terms	of	 level	of	evidence,	65	
taking	into	account	the	study	design	and	quality.	Finally,	an	advanced	search	of	guidance	on	the	use	66	
of	radiotherapy	was	performed,	namely	focusing	on	NICE	Guidelines	(NICE.,	2010).	In	each	included	67	
article,	we	 actively	 searched	 for	 specific	 outcome	measures.	 These	 included	 the	 disease	 response	68	
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outcome	(regression	rate,	disease	stability	or	progression	rate),	 short	and	 long-term	complications	69	
of	 radiotherapy	 and	 the	 conversion	 rate	 to	 surgery.	 The	 search	 and	 review	 process	 was	 initially	70	
performed	by	two	independent	authors	based	on	analysis	of	the	study	title	and	abstract	(Table	1).	71	
Before	 analysis	 of	 the	 full	 text,	 another	 independent	 author	was	 used	 as	 a	 referee	 for	 the	 initial	72	
screening	process.	This	process	was	then	repeated	for	the	full	text	analysis.	The	PRISMA	statement	73	
guidelines	were	adhered	to	throughout	this	systematic	review.		74	
Table	1:	Screening	questions	75	
	76	
Results	77	
A	 search	 in	 the	 Cochrane	 database	 revealed	 no	 published	 review	 articles	 on	 radiotherapy	 in	78	
Dupuytren’s	 disease.	 A	 total	 of	 39	 articles	were	 found	 on	 PubMed	 and	 227	 using	 Google	 Scholar	79	
(Supplementary	Figure	1).	Only	six	articles	met	our	strict	inclusion	criteria	(Table	1).	These	six	articles	80	
had	 a	 cumulative	 cohort	 of	 698	 patients	 with	 Dupuytren’s	 disease	 with	 a	 total	 of	 770	 irradiated	81	
hands.	 The	mean	age	was	58.5	 years.	 Staging	of	disease	was	performed	via	 the	modified	Tubiana	82	
classification	in	all	articles,	which	is	based	on	the	total	flexion	deformity	or	extension	deficit	of	the	83	
involved	MP	and	PIP	finger	joints	(Stage	N:	no	flexion	deformity,	stage	N/I:	1-5o,	stage	I:	6-45o,	stage	84	
II:	 46-90o,	 stage	 III:	 91-135o,	 stage	 IV:	 >135o)	 (Keilholz	 et	 al.,	 1996;	 Seegenschmiedt	 et	 al.,	 2001).	85	
According	to	the	Tubiana	classification,	47.2%	were	stage	N,	16%	were	stage	N/I,	30.2%	were	stage	I,	86	
Question	 Minimum	Criteria		
Does	it	address	the	study	question?		
Does	it	address	the	topic?		
Is	it	a	clinical	study?		
What	is	the	level	of	evidence?		
How	many	patients	were	included?		
Does	it	address	outcome	measures?	
	
Radiotherapy	treatment	
Dupuytren’s	disease	
Yes	
Case	series		
N	>	10	
Any	of:	Progression	rates,	stability	rates,	
regression	rates,	conversion	to	surgery	and	
complication	rates.		
5	
	
5.1%	were	 stage	 II,	 0.9%	were	 stage	 III	 and	 0.5%	were	 stage	 IV.	 Interestingly,	 there	was	 a	 higher	87	
proportion	of	 females	 in	 the	 included	 studies	 (male	 to	 female	 ratio	of	1.6:1)	 compared	 to	what	 is	88	
typically	observed	in	practice	(male	to	female	ratio	of	3:1).	This	may	be	due	to	a	preference	towards	89	
radiotherapy	treatment	rather	than	surgical	management	in	females.		90	
	91	
Five	 of	 the	 six	 articles	 utilised	 a	 retrospective	 cohort	 study	 design,	 whilst	 one	 was	 a	 prospective	92	
randomised	 controlled	 study	 (Table	 2).	 All	 six	 studies	 were	 performed	 in	 Germany.	 The	 total	93	
radiation	dose	ranged	from	21	to	42	Gy,	with	30	Gy	being	most	commonly	used	(Table	2),	and	doses	94	
were	fractionated	to	deliver	3	Gy	per	 fraction	or	8	Gy	per	 fraction.	The	median	follow-up	was	 five	95	
years	(range:	1-13	years).	Three	main	outcome	measures	were	assessed,	namely	disease	regression	96	
(reduction	in	the	number	and	consistency	of	cords	or	nodules	and	a	reduction	in	extension	deficit),	97	
stability	 (neither	regression	or	progression	of	disease	according	to	objective	clinical	measures)	and	98	
progression.	Three	studies	reported	overall	results	across	all	stages,	between	0-56%	for	regression,	99	
37-98%	 for	 stability,	 and	 2-20%	 for	 progression	 (Herbst	 and	 Regler.,	 1986;	 Seegenschmiedt	 et	 al.,	100	
2001;	Zirbs	et	al.,	2015).		The	other	three	studies	reported	results	separately	for	each	Tubiana	stage:	101	
6-16%	 (stage	 N),	 12-30%	 (stage	 N/I),	 6-20%	 (stage	 I)	 and	 0-38%	 (stage	 II)	 for	 regression;	 21-81%	102	
(stage	N),	12-54%	(stage	N/I),	20-32%	(stage	I)	and	14-62%	(stage	II)	for	stability;	13-16%	(stage	N),	103	
30-33%	 (stage	 N/I),	 62-65%	 (stage	 I)	 and	 83-86%	 (stage	 II)	 for	 progression	 (Keilholz	 et	 al.,	 1997;	104	
Adamietz	et	al.,	2001;	Betz	et	al.,	2010)	(Supplementary	Table	1).		105	
	106	
	107	
	108	
	109	
	110	
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Table	2:	The	type,	total	dosage	and	follow-up	length	for	each	included	study.		111	
	112	
	113	
	114	
	115	
	116	
	117	
	118	
	119	
	120	
	121	
	122	
	123	
The	randomised	controlled	trial	by	Seegenschmiedt	et	al.	(2001)	is	the	best	quality	paper	available	to	124	
us.		This	study	did	not	include	an	untreated	control	however	and	we	have	downgraded	it	from	level	125	
1	evidence	to	level	2.	The	authors	randomised	Dupuytren’s	patients	to	receive	either	10	fractions	of	126	
3	Gy	(total	dose	30	Gy,	Group	A)	or	7	fractions	of	3	Gy	(total	dose	21	Gy,	Group	B).	Group	A	consisted	127	
of	 63	patients	 (95	hands),	whilst	 group	B	had	66	patients	 (103	hands).	 There	were	no	 statistically	128	
significant	demographic	differences	between	groups	A	and	B	and	disease	stages	were	similar.		Both	129	
subjective	 (patient	 assessed)	 and	 objective	 measures	 (physician	 assessed	 via	 inspection	 for	 skin	130	
fixation,	skin	retraction	and	measurements	of	nodules,	cords	and	the	degree	of	extension	deficit)	of	131	
disease	 regression,	 stability	 and	 progression	 rates	 were	 compared	 to	 results	 measured	 prior	 to	132	
radiotherapy,	highlighting	a	 statistically	 significant	 improvement	 (p	<	0.01)	 (Seegenschmiedt	et	al.,	133	
2001).	 No	 statistically	 significant	 difference	 in	 objective	 measurements	 existed	 between	 the	 two	134	
radiation	doses,	although	this	may	reflect	the	relatively	short	one-year	follow-up	used	in	the	study.		135	
The	 proportion	 of	 patients	 undergoing	 surgery	 because	 of	 disease	 progression	 following	136	
radiotherapy	 ranged	 from	 3.1-10%	 (Adamietz	 et	 al.,	 2001;	 Betz	 et	 al.,	 2010;	 Keilholz	 et	 al.,	 1996;	137	
Study (year)  Type of 
study 
MRC 
level  of  
evidence 
Total  
dose of  
Radioth
erapy 
Number 
of  
fract ion
s 
Dose 
per 
fract ion 
(Gy) 
Mean 
fol low-
up 
length 
(years)  
     
Herbst and 
Regler  (1985) 
Retrospective 
cohort 
3 <42 Gy 3-14  3 1.5 
Kei lholz  et  a l .  
(1997) 
Retrospective 
cohort  
3 30 Gy 10 3 6 
Adamietz et  a l .  
(2001) 
Retrospective 
cohort 
3 30 Gy 10 3 10  
Seegenschmiedt 
et  a l .  (2001) 
Randomised 
controlled 
study 
2 30 Gy 10  3 1 
 21 Gy 7  3  
Betz et  a l .  
(2010) 
Retrospective 
cohort 
3 <30 Gy 2  3 13 
Zirbs et  a l .  
(2015) 
Retrospective 
cohort 
3 32 Gy 4   8 4   
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Seegenschmiedt	et	al.,	2001).	Salvage	surgery	was	successful	in	all	cases	(Adamietz	et	al.,	2001;	Betz	138	
et	 al.,	 2010;	 Keilholz	 et	 al.,	 1996;	 Seegenschmiedt	 et	 al.,	 2001).	 Radiotherapy	 did	 not	 appear	 to	139	
increase	complication	rates	of	surgical	treatment	in	the	short	and	long-term	(Adamietz	et	al.,	2001;	140	
Betz	 et	 al.,	 2010;	 Keilholz	 et	 al.,	 1996;	 Seegenschmiedt	 et	 al.,	 2001),	 but	 none	 of	 the	 papers	141	
addressed	this	in	depth.	142	
Long-term	 outcomes	 were	 reassessed	 in	 four	 studies	 by	 a	 self-reported	 questionnaire.	 Relief	 of	143	
symptoms	 such	 as	 sensations	 of	 tightness	 and	 pruritus	 were	 reported	 in	 66	 to	 87%	 of	 patients	144	
following	irradiation.	Four	studies	measured	short-term	complications,	which	occurred	in	20	to	43%	145	
of	 patients	 and	 included	 erythema,	 drying	 of	 the	 skin	 and	 desquamation	 (Supplemental	 Table	 1).	146	
Long-term	 complications	 were	 assessed	 by	 four	 studies	 and	 included	 skin	 dryness	 (5-64%)	 and	147	
atrophy	(5-13%).	No	cases	of	skin	ulceration	or	radiation-induced	malignancy	have	been	reported.		148	
	149	
Discussion	150	
Radiotherapy	 is	 currently	 used	 in	 Dupuytren’s	 disease	 with	 the	 intention	 to	 stabilise	 disease	151	
progression,	 thereby	 delaying	 or	 preventing	 surgical	 intervention.	 In	 this	 systematic	 review,	 we	152	
analysed	six	studies	that	delivered	similar	radiation	schedules.	The	majority	of	patients	 included	 in	153	
these	studies	(93%)	were	Tubiana	stage	N,	N/I	or	I.	The	studies	all	suggest	an	improvement	in	overall	154	
outcome,	with	significant	degrees	of	remission	and	stabilisation,	although	none	of	these	studies	had	155	
an	untreated	control	 group.	 Early	use	of	 radiotherapy	may	 lead	 to	a	more	 favourable	outcome	as	156	
demonstrated	 by	 improved	 disease	 regression	 and	 decreased	 progression	 in	 stages	 N	 and	 N/1	157	
compared	to	stage	2	(Adamietz	et	al.,	2001;	Betz	et	al.,	2010).		Only	one	of	the	six	studies	reviewed	158	
(Keilholz	et	al.,	1996)	reported	better	outcomes	in	more	advanced	disease	compared	to	early-stage	159	
Dupuytren’s.	Updated	NICE	guidelines	 for	 the	 treatment	of	Dupuytren’s	disease	with	 radiotherapy		160	
(NICE.,	 Dec	 2016)	 comment	 on	 the	 limited	 availability	 of	 evidence	 and	 recommends	 that	161	
radiotherapy	should	only	be	used	with	“special	arrangements	for	clinical	governance,	consent,	audit	162	
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and	 research”.	NICE	highlight	 that	 the	use	of	 radiotherapy	 in	Dupuytren’s	disease	aims	 to	prevent	163	
progression	 and	 prevent	 surgery.	 However,	 not	 all	 cases	 of	 Dupuytren’s	 disease	 progress.	 For	164	
example,	 a	 recent	 study	 describing	 the	 short-term	 disease	 course	 of	 Dupuytren’s	 disease	 in	 247	165	
participants	showed	that	up	to	75%	of	patients	have	differing	patterns	of	progression,	stability	and	166	
regression	(Lanting	et	al.,	2016).	In	an	18	year	follow-up	of	Dupuytren’s	disease	progression,	35%	of	167	
patients	 with	 early	 Dupuytren’s	 disease	 (stage	 N)	 progressed	 to	 develop	 contractures	168	
(Gudmundsson	 et	 al.,	 2001).	 This	 is	 a	 higher	 rate	 of	 progression	 than	 those	 treated	 with	169	
radiotherapy,	but	no	direct	comparison	can	be	made	as	the	follow	up	times	for	patients	treated	with	170	
radiotherapy	were	 shorter.	One	other	 study	with	a	 shorter	 follow-up	of	8.7	 years	 found	 that	only	171	
8.5%	of	patient’s	disease	progressed	sufficiently	 to	warrant	surgical	 treatment	 (Reilly	et	al.,	2005).	172	
Therefore,	the	use	of	radiotherapy	may	impose	unnecessary	treatment	on	patients,	along	with	side	173	
effects	and	long-term	risks.		174	
As	expected,	both	acute	(erythema)	and	late	(skin	atrophy)	side	effects	were	observed	in	irradiated	175	
patients.	 Approximately	 20-40%	 of	 patients	 experienced	 acute	 complications	 with	 less	 than	 10%	176	
experiencing	late	changes.	No	radiation-induced	malignancies	were	reported	but	the	median	follow-177	
up	across	all	studies	of	five	years	is	insufficient	(Hall	and	Giaccia.,	2006;	Trott	and	Kamprad.,	2006).	178	
The	increase	in	absolute	risk	of	radiation-induced	malignancies	has	previously	been	estimated	to	be	179	
0.02%	(Dupuytren's	International	Society.,	2013).	180	
From	 the	 available	 evidence,	 salvage	 surgery	 for	 disease	 progression	 after	 radiotherapy	 may	 be		181	
feasible	 but	 the	 available	 data	 is	 poor.	 The	 authors	 report	 that	 progression	of	 symptoms	was	 the	182	
main	 indication	 for	 surgery,	 but	 fail	 to	 address	 the	 threshold	 for	operative	management	 in	detail.	183	
Specific	 types	 or	 numbers	 of	 complications	 after	 conversion	 to	 surgery	 were	 not	 reported.	184	
Furthermore,	complication	rates	of	salvage	surgery	post-radiotherapy	were	not	compared	to	those	185	
after	surgery	in	radiation-naive	hands.		186	
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Although	the	studies	seem	to	show	a	benefit	in	early	Dupuytren’s	disease,	various	limitations	exist.	187	
Five	 of	 six	 articles	were	 retrospective	 cohort	 studies	with	 a	modest	 number	 of	 patients	 included.	188	
Patient-reported	outcomes	were	more	subjective	and	may	have	been	susceptible	to	response	bias.	189	
The	 one	 randomised	 study	 compared	 two	 treatment	 groups,	 therefore	 lacking	 a	 control	 group	 to	190	
compare	 radiotherapy	 with	 other	modalities	 of	 treatment	 or	 no	 treatment.	 The	 safety	 outcomes	191	
measured	 in	 the	 RCT	 were	 reported	 collectively,	 rather	 than	 being	 group-specific,	 leading	 to	192	
difficulty	 in	analysing	the	safety	of	radiotherapy	 in	different	stages	of	disease.	Although	 irradiation	193	
protocols	 were	 largely	 similar,	 some	 differences	 existed	 in	 fractionation	 schedules.	 Biological	194	
equivalent	dose	calculations	would	be	useful	in	order	to	meaningfully	compare	doses	from	different	195	
schedules.	 Furthermore,	 half	 of	 the	 studies	 reviewed	 did	 not	 differentiate	 between	 the	 stage	 of	196	
Dupuytren’s	treated,	which	must	be	considered	a	flaw	since	the	literature	suggests	radiotherapy	is	197	
most	 efficacious	 in	 early	 stages.	 Limitations	 may	 also	 exist	 in	 the	 review	 mainly	 as	 a	 result	 of	198	
incomplete	 retrieval	 of	 published	 papers.	 The	 authors	 did	 attempt	 to	 minimise	 this	 risk	 by	199	
performing	three	cycles	of	advanced	searches	on	each	database.		200	
On	balance,	the	evidence	for	the	use	of	radiotherapy	in	early	Dupuytren’s	disease	is	weak	and	does	255	
not	 clearly	 support	 its	 use	 in	 practice.	Well-designed,	 randomised	 control	 studies	 are	 required	 to	256	
elucidate	 its	 efficacy	 further	 and	 its	 place	 in	 the	 evidence-based	 management	 of	 Dupuytren’s	257	
disease.	This	 requires	high-level	co-operation	between	clinical	oncologists	and	hand	surgeons	with	258	
careful	study	design	and	recruitment.		259	
	260	
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